Ken Griffin Obs Eva Sa Transaction History

Citadel Advisors LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 16, 2022	SELL	$1.1 - $2.17 $70,462 - $139,003	-64,057 Reduced 74.84%	21,531 $33,000
Q4 2021 Feb 14, 2022	SELL	$1.99 - $3.1 $39,945 - $62,226	-20,073 Reduced 19.0%	85,588 $170,000
Q3 2021 Nov 15, 2021	SELL	$2.47 - $3.34 $368 - $497	-149 Reduced 0.14%	105,661 $328,000
Q2 2021 Aug 16, 2021	SELL	$2.56 - $3.35 $189,340 - $247,769	-73,961 Reduced 41.14%	105,810 $320,000
Q1 2021 May 17, 2021	BUY	$2.01 - $5.05 $337,997 - $849,197	168,158 Added 1448.02%	179,771 $584,000

Q2 2020 Aug 14, 2020	SELL	$2.01 - $5.95 $2,084 - $6,170	-1,037 Reduced 8.2%	11,613 $68,000
Q1 2020 May 15, 2020	SELL	$1.87 - $4.47 $29,355 - $70,170	-15,698 Reduced 55.38%	12,650 $30,000
Q4 2019 Feb 14, 2020	SELL	$2.48 - $8.1 $29,834 - $97,443	-12,030 Reduced 29.79%	28,348 $108,000
Q3 2018 Nov 13, 2018	BUY	$10.92 - $18.18 $440,927 - $734,072	40,378 New	40,378 $0

88K

Ticker OBSV
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 84,499,200
Description
ObsEva SA, a biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for women suffering from reproductive health and pregnancy. It is developing Linzagolix, an oral gonadotropin releasing hormone receptor antagonist that is in Phase III clinical trial for the treatment of pain associated with endometrio...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.